By Russia has announced the development of an mRNA-based cancer vaccine, with plans to distribute it free of charge to patients starting in early 2025.
The vaccine aims to activate the immune system to recognize and destroy cancer cells, potentially slowing tumor growth, preventing recurrences, and even eliminating certain early-stage cancers.
Pre-clinical trials have demonstrated that the vaccine can suppress tumor development and prevent metastasis.
Additionally, researchers are leveraging artificial intelligence to personalize the vaccine, potentially reducing the time required for customization to less than an hour.
While the announcement has generated optimism, experts emphasize the need for rigorous clinical trials to confirm the vaccine’s safety and efficacy before it becomes widely available.
